electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
05 Agosto 2022 - 9:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine company, today announced that electroCore’s Chief
Executive Officer, Dan Goldberger, will be presenting at the
Canaccord Genuity 42nd Annual Growth Conference.
Canaccord
Genuity 42nd Annual Growth ConferenceDate: Thursday,
August 11, 2022Time: 8:30 AM EDTWebcast: Canaccord Webcast
Following the conferences, a webcast replay of the presentations
will be available on the Investor section of the company’s website,
electroCore.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine company dedicated to
improving patient outcomes through its non-invasive vagus nerve
stimulation therapy platform, initially focused on the treatment of
multiple conditions in neurology. The company's current indications
are the preventive treatment of cluster headache and migraine, the
acute treatment of migraine and episodic cluster headache, the
acute and preventive treatment of migraines in adolescents, and
paroxysmal hemicrania and hemicrania continua in adults.For more
information, visit
www.electrocore.com.Investors:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024